Deutsche Bank’s Maze Therapeutics MAZE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$875K Sell
32,205
-2,788
-8% -$77.4K ﹤0.01% 2311
2026
Q2
$1.04M Buy
34,993
+14,730
+73% +$386K ﹤0.01% 2324
2026
Q1
$605K Buy
20,263
+4,741
+31% +$209K ﹤0.01% 2472
2025
Q4
$643K Buy
15,522
+6,637
+75% +$228K ﹤0.01% 2439
2025
Q3
$230K Hold
8,885
– – ﹤0.01% 2989
2025
Q2
$109K Hold
8,885
– – ﹤0.01% 3218
2025
Q1
$97.8K Buy
+8,885
New +$107K ﹤0.01% 3203

Other funds holding MAZE

Deutsche Bank's MAZE Position: Q3 2026 in Review

Deutsche Bank reduced its Maze Therapeutics (MAZE) stake by 8% in Q3 2026, selling an estimated $77.4K and leaving 32,205 shares worth $875K. The position accounts for ﹤0.01% of the portfolio, ranked #2311.

Deutsche Bank first reported a position in MAZE in Q1 2025 and has held it in 7 quarters since. The position peaked at $1.04M in Q2 2026. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Deutsche Bank held 32,205 shares of Maze Therapeutics worth $875K as of Q3 2026.
  • Deutsche Bank sold 2,788 Maze Therapeutics shares in Q3 2026, an estimated $77.4K.
  • Maze Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #2311 holding.
  • Deutsche Bank first reported a position in Maze Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Deutsche Bank's Maze Therapeutics position peaked at $1.04M in Q2 2026.
  • 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.